Speakers

This was followed by 3 years as a Presidential Fellow at Novartis, Cambridge, MA) where he worked with Prof Teresa Compton investigating the mechanisms of viral entry and the importance of cell signalling for establishment of viral latency. He returned to the UK with a prestigious 6 year Medical Research Council Fellowship establishing his lab first at Cambridge, UK before moving to UCL. It was at UCL Matthew formed a productive relationship with Prof Paul Griffiths seeking to understand the mechanistic basis of partial protection afforded by a HCMV vaccine based on the fusion protein glycoprotein B. A major advance being the identification of a novel humoral immune response that could explain protection in phase II vaccine trials of gB/MF59. His programme of work on vaccines remains a major theme of the lab alongside their longstanding interest in the molecular mechanisms governing viral persistence and pathogenesis in vivo.